Update on Haemophilus influenzae serotype b and meningococcal vaccines.
Use of conjugate Haemophilus influenzae type b (Hib) vaccines has resulted in the near elimination of Hib invasive disease among infants in the United States in only 10 years, which places this intervention among the most notable public health achievements of the past decade. This has radically altered our perception of the major causes of bacterial meningitis and invasive bacterial disease among children, increasing the prominence of meningococcal disease as an important cause of childhood and adult meningitis and leading researchers to apply the same conjugate technology to the development of improved vaccines for Neisseria meningitidis. Use of conjugated meningococcal vaccines against serogroups A, C, Y, and W-135 are expected to offer the possibility of better control of sporadic disease and outbreaks throughout developed and developing countries within the next 5 years.
Rosenstein
N E
NE
Meningitis and Special Pathogens Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. NAR5@cdc.gov
Perkins
B A
BA
D001428:Bacterial Vaccines; D002648:Child; D006192:Haemophilus Infections / Q000382:microbiology; D018073:Haemophilus Vaccines; D019741:Haemophilus influenzae type b; D006801:Humans; D008589:Meningococcal Infections / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control; D018074:Vaccines, Conjugate
D001428:Bacterial Vaccines; D018073:Haemophilus Vaccines; D018074:Vaccines, Conjugate